לברסט

Страна: Ізраїль

мова: іврит

Джерело: Ministry of Health

Активний інгредієнт:

LETROZOLE 2.5 MG

Доступна з:

RAFA LABORATORIES LTD

Код атс:

L02BG04

Фармацевтична форма:

FILM COATED TABLETS

Адміністрація маршрут:

PER OS

Виробник:

SIEGFRIED GENERICS ( MALTA) LTD

Терапевтична група:

LETROZOLE

Терапевтичні свідчення:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Дата Авторизація:

2012-04-01